310 related articles for article (PubMed ID: 27157252)
1. Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance.
Mikulasova A; Smetana J; Wayhelova M; Janyskova H; Sandecka V; Kufova Z; Almasi M; Jarkovsky J; Gregora E; Kessler P; Wrobel M; Walker BA; Wardell CP; Morgan GJ; Hajek R; Kuglik P
Eur J Haematol; 2016 Dec; 97(6):568-575. PubMed ID: 27157252
[TBL] [Abstract][Full Text] [Related]
2. Identification and monitoring of Copy Number Variants (CNV) in monoclonal gammopathy.
Sallustio F; Curci C; Solimando AG; Leone P; Pontrelli P; Gesualdo L; Vacca A; Racanelli V; Gallone A
Cancer Biol Ther; 2021 Jun; 22(5-6):404-412. PubMed ID: 34288806
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders.
Stella F; Pedrazzini E; Baialardo E; Fantl DB; Schutz N; Slavutsky I
Blood Cells Mol Dis; 2014 Sep; 53(3):110-7. PubMed ID: 24973170
[TBL] [Abstract][Full Text] [Related]
4. Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients.
Brousseau M; Leleu X; Gerard J; Gastinne T; Godon A; Genevieve F; Dib M; Lai JL; Facon T; Zandecki M;
Clin Cancer Res; 2007 Oct; 13(20):6026-31. PubMed ID: 17947464
[TBL] [Abstract][Full Text] [Related]
5. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
[TBL] [Abstract][Full Text] [Related]
6. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status.
López-Corral L; Sarasquete ME; Beà S; García-Sanz R; Mateos MV; Corchete LA; Sayagués JM; García EM; Bladé J; Oriol A; Hernández-García MT; Giraldo P; Hernández J; González M; Hernández-Rivas JM; San Miguel JF; Gutiérrez NC
Leukemia; 2012 Dec; 26(12):2521-9. PubMed ID: 22565645
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects.
Seth S; Zanwar S; Vu L; Kapoor P
Curr Hematol Malig Rep; 2020 Apr; 15(2):45-55. PubMed ID: 32222885
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
10. Genomewide association study on monoclonal gammopathy of unknown significance (MGUS).
Thomsen H; Campo C; Weinhold N; da Silva Filho MI; Pour L; Gregora E; Vodicka P; Vodickova L; Hoffmann P; Nöthen MM; Jöckel KH; Langer C; Hajek R; Goldschmidt H; Hemminki K; Försti A
Eur J Haematol; 2017 Jul; 99(1):70-79. PubMed ID: 28375557
[TBL] [Abstract][Full Text] [Related]
11. Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events.
Landgren O
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):662-672. PubMed ID: 34889381
[TBL] [Abstract][Full Text] [Related]
12. Burden of cytogenetically abnormal plasma cells in light chain amyloidosis and their prognostic relevance.
Kim SY; Im K; Park SN; Kim JA; Yoon SS; Lee DS
Leuk Res; 2016 May; 44():45-52. PubMed ID: 27015231
[TBL] [Abstract][Full Text] [Related]
13. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance.
Ross FM; Chiecchio L; Dagrada G; Protheroe RK; Stockley DM; Harrison CJ; Cross NC; Szubert AJ; Drayson MT; Morgan GJ;
Haematologica; 2010 Jul; 95(7):1221-5. PubMed ID: 20410185
[TBL] [Abstract][Full Text] [Related]
14. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
Zhan F; Barlogie B; Arzoumanian V; Huang Y; Williams DR; Hollmig K; Pineda-Roman M; Tricot G; van Rhee F; Zangari M; Dhodapkar M; Shaughnessy JD
Blood; 2007 Feb; 109(4):1692-700. PubMed ID: 17023574
[TBL] [Abstract][Full Text] [Related]
15. Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma.
Greenberg AJ; Cousin M; Kumar S; Ketterling RP; Knudson RA; Larson D; Colby C; Scott C; Vachon CM; Vincent Rajkumar S
Eur J Haematol; 2013 Sep; 91(3):193-195. PubMed ID: 23647020
[TBL] [Abstract][Full Text] [Related]
16. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
Mailankody S; Mena E; Yuan CM; Balakumaran A; Kuehl WM; Landgren O
Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
[TBL] [Abstract][Full Text] [Related]
17. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma.
Kaufmann H; Ackermann J; Baldia C; Nösslinger T; Wieser R; Seidl S; Sagaster V; Gisslinger H; Jäger U; Pfeilstöcker M; Zielinski C; Drach J
Leukemia; 2004 Nov; 18(11):1879-82. PubMed ID: 15385925
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.
Schmidt-Hieber M; Gutiérrez ML; Pérez-Andrés M; Paiva B; Rasillo A; Tabernero MD; Sayagués JM; Lopez A; Bárcena P; Sanchez ML; Gutiérrez NC; San Miguel JF; Orfao A
Haematologica; 2013 Feb; 98(2):279-87. PubMed ID: 22929983
[TBL] [Abstract][Full Text] [Related]
19. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic patterns in multiple myeloma after a phase of preceding MGUS.
Kaufmann H; Ackermann J; Odelga V; Sagaster V; Nösslinger T; Pfeilstöcker M; Keck A; Ludwig H; Gisslinger H; Drach J
Eur J Clin Invest; 2008 Jan; 38(1):53-60. PubMed ID: 18173551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
